Jpmorgan Chase & CO Akebia Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

$1.23 Trillion
Q4 2024

A detailed history of Jpmorgan Chase & CO transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 456,294 shares of AKBA stock, worth $844,143. This represents 0.0% of its overall portfolio holdings.

Number of Shares

456,294

Previous 98,546 363.03%

Holding current value

$844,143

Previous $130,000 552.31%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 12, 2025	BUY	$1.26 - $2.13 $450,762 - $762,003	357,748 Added 363.03%	456,294 $848,000
Q3 2024 Dec 26, 2024	BUY	$0.94 - $1.55 $9,082 - $14,976	9,662 Added 10.87%	98,546 $130,000
Q3 2024 Nov 08, 2024	BUY	$0.94 - $1.55 $9,082 - $14,976	9,662 Added 10.87%	98,546 $130,000
Q2 2024 Dec 26, 2024	SELL	$0.86 - $1.63 $8,309 - $15,749	-9,662 Reduced 9.8%	88,884 $90,000
Q2 2024 Aug 12, 2024	BUY	$0.86 - $1.63 $76,241 - $144,504	88,653 Added 38377.92%	88,884 $90,000
Q1 2024 Dec 26, 2024	SELL	$1.27 - $2.24 $124,860 - $220,225	-98,315 Reduced 99.77%	231 $0
Q4 2023 Dec 26, 2024	SELL	$0.8 - $1.28 $78,652 - $125,843	-98,315 Reduced 99.77%	231 $0
Q4 2023 Feb 12, 2024	SELL	$0.8 - $1.28 $75,694 - $121,111	-94,618 Reduced 99.76%	231 $0
Q3 2023 Nov 14, 2023	BUY	$0.87 - $1.84 $49,543 - $104,780	56,946 Added 150.24%	94,849 $108,000
Q2 2023 Aug 11, 2023	SELL	$0.51 - $1.43 $22,258 - $62,410	-43,644 Reduced 53.52%	37,903 $34,000
Q1 2023 May 11, 2023	BUY	$0.56 - $1.15 $43,401 - $89,128	77,503 Added 1916.49%	81,547 $45,000
Q4 2022 Feb 13, 2023	SELL	$0.25 - $0.58 $1,836 - $4,261	-7,347 Reduced 64.5%	4,044 $2,000
Q3 2022 Nov 14, 2022	BUY	$0.3 - $0.46 $1,251 - $1,918	4,171 Added 57.77%	11,391 $4,000
Q2 2022 Aug 11, 2022	SELL	$0.32 - $0.67 $1.36 Million - $2.85 Million	-4,250,978 Reduced 99.83%	7,220 $3,000
Q1 2022 May 11, 2022	SELL	$0.72 - $2.93 $125,283 - $509,834	-174,005 Reduced 3.93%	4,258,198 $3.06 Million
Q4 2021 Feb 10, 2022	SELL	$2.26 - $3.34 $301,782 - $445,996	-133,532 Reduced 2.92%	4,432,203 $10 Million
Q3 2021 Nov 12, 2021	BUY	$2.35 - $3.88 $10.7 Million - $17.7 Million	4,565,735 New	4,565,735 $13.2 Million

Others Institutions Holding AKBA

# of Institutions

128

Shares Held

63.3M

Call Options Held

50.6K

Put Options Held

203K

View Full List

About Akebia Therapeutics, Inc.

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $340M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

More about AKBA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Akebia Therapeutics, Inc. Transaction History